Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783708 | 0.95 | RORC (0.42) | RORCTYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL784793 | 0.91 | TAS1R3 (0.45) | RORCTYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL27920485 | 0.89 | SMO (0.39) | TAS1R3TAS1R1TAS1R2IRAK4ROCK2 | |
| SCHEMBL784009 | 0.87 | RORC (0.40) | RORCTYK2F10RIPK1ROCK2 | |
| SCHEMBL785698 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2F10 | |
| SCHEMBL785404 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2F10 | |
| SCHEMBL785681 | 0.86 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2F10RIPK1 | |
| SCHEMBL784148 | 0.86 | RORC (0.41) | RORCTYK2F10IRAK4ROCK2 | |
| SCHEMBL784059 | 0.86 | RORC (0.39) | RORCTYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL784482 | 0.86 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2F10ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | RORC 4667/4885TYK2 3974/4885TAS1R3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.